Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Coronary artery medicinal-coating stent

A technology of drug coating and coronary artery, applied in stent, medical science, prosthesis, etc., can solve the problem of unsatisfactory overall effect and other problems

Inactive Publication Date: 2009-06-03
SOUTHEAST UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In view of the above mechanism, the clinical use of antiplatelet drugs and anticoagulant drugs has greatly reduced the chance of thrombosis, and for neointimal hyperplasia, intravascular brachytherapy has also been tried in recent years, but the overall effect is not satisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coronary artery medicinal-coating stent
  • Coronary artery medicinal-coating stent
  • Coronary artery medicinal-coating stent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] A coronary drug-coated stent for inhibiting intimal proliferation and preventing in-stent restenosis, comprising: an expandable stent base 1, an inner coating 2 is coated on the expandable stent base 1, and the inner coating 2 It consists of a drug carrier and ligustrazine, and its mass ratio is: 3:1 to 1:3. In this embodiment, its mass ratio can be selected as 3:1, 1:3 or 2:2. The above-mentioned drug carrier is methyl acrylate ester, methyl methacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly-racemic lactic acid, polylactide-glycolide polymer, phosphorylcholine, polyurethane, inorganic microporous A combination of one or more of aluminum oxide and cellulose. In this embodiment, the inner coating 2 can also be coated with an outer coating 3, and the outer coating 3 is methyl acrylate, methyl methacrylate copolymer, polylactic acid (PLLA), polyglycolic acid, poly-sterile A composition coating of one or more of spiral lactide, polylactide-glycolide po...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a coronary artery medicine coating scaffold for inhibiting endometrial hyperplasia and preventing restenosis in the scaffold. It includes dilating scaffold base body and inner coating layer coated on the dilating scaffold base body, the above-mentioned inner coating layer is formed from medicine carrier and ligustrazine, their mass ratio is 3:1-1:3, the above-mentioned inner coating layer is one of methyl acrylate, methyl methacrylate copolymer, polylactic acid, polyglycollic acid, polymonoracemic lactic acid, polylactide-diglycolide polymer, phosphorylcholine, ethyl polyurethane inorganic micropore aluminium oxide and cellulose or their composite.

Description

technical field [0001] The invention relates to a stent implanted in a human body, in particular to a coronary drug-coated stent for inhibiting intima proliferation and preventing restenosis in the stent. Background technique [0002] In the past ten years, coronary artery stent implantation has become an important method with definite curative effect in the treatment of coronary heart disease, and it has been more and more widely used in the treatment of coronary heart disease. development of. [0003] Clarifying the pathophysiology and pathogenesis of in-stent restenosis is the key to preventing in-stent restenosis. In recent years, it has been agreed that the early stage of stent implantation can cause endothelial stripping, exposing components such as collagen, vWF factor, fibronectin and laminin to the blood, promoting platelet adhesion and aggregation, and forming thrombus in the stent; The injury to the vessel wall or the rupture of the lipid core after entry can ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61L27/54A61L27/40A61L31/16A61L31/12A61F2/82
Inventor 马根山冯毅陈忠张晓黎丁澍陈立娟
Owner SOUTHEAST UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com